title: Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial.
abstract: OBJECTIVE
  To evaluate patient assessment of long-term effect of pelvic radiotherapy on bowel function.
  
  
  METHODS
  As part of a prospective randomized trial evaluating the impact of sucralfate on bowel function in patients receiving pelvic radiotherapy, patient-assessed bowel function data were collected during radiotherapy and again at 4 weeks and 1 year after completion of radiotherapy.
  
  
  RESULTS
  The number of bowel movements per day increased up to week 4 and then slowly decreased. At 1 year, the mean number of bowel movements per day had increased from 1.75 to 2.09 and the median from 1 to 2. All measures of adverse bowel function worsened during radiotherapy. Frequency of bowel movements and symptoms of frequency, nocturnal bowel movements, cramping, and bleeding returned close to baseline values by 1 year. Symptoms of urgency, clustering, and measures of incontinence were all persistent at 1 year. The mean increase in bowel function score at 1 year was 0.74 (range, -5 to 7).
  
  
  CONCLUSIONS
  Pelvic radiotherapy is associated with a slight increase in bowel movement frequency and decrease in several patient-reported measures of adverse bowel function. Several measures of adverse function persisted at 1 year.
authors.affiliation: Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA. haddock.michael@mayo.edu
authors.forename: Michael G
authors.initials: MG
authors.lastname: Haddock
authors.forename: Jeff A
authors.initials: JA
authors.lastname: Sloan
authors.forename: John W
authors.initials: JW
authors.lastname: Bollinger
authors.forename: Gamini
authors.initials: G
authors.lastname: Soori
authors.forename: Preston D
authors.initials: PD
authors.lastname: Steen
authors.forename: James A
authors.initials: JA
authors.lastname: Martenson
mesh_terms: D003672:Defecation / Q000528:radiation effects*; D004311:Double-Blind Method; D006801:Humans; D010388:Pelvis / Q000528:radiation effects*; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects*; D013392:Sucralfate / Q000627:therapeutic use
chemical_list: D013392:Sucralfate